ArticleFrontiers in medicine2026
Ozone therapy in femoral head necrosis: a perspective on biomarker-guided treatment rationalization and mechanistic exploration.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Femoral head necrosis (FHN) is a progressive and disabling disorder caused by compromised blood supply to the femoral head. Current treatments primarily aim to slow progression. However, they often fail to reverse early-stage necrosis or reliably prevent disease advancement. Importantly, most approaches lack precise molecular targets for early intervention. Ozone therapy has emerged as a potential option because of its pleiotropic biological effects, such as modulating oxidative stress, improving microcirculation, and exerting anti-inflammatory activity. However, its mechanisms remain poorly understood. Clinical evidence is limited and inconsistent, and the absence of standardized protocols hinders evidence-based implementation. To address these gaps, this perspective proposes biomarkers as a translational bridge linking ozone-induced biological responses to FHN pathology. We further outline a dynamic, biomarker-guided framework through which ozone therapy can evolve from an empirical intervention into a mechanism-informed, personalized, and more standardized precision strategy. This approach offers a scientifically grounded pathway for advancing the clinical management of FHN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.